This article is more than 5 years old. Information may no longer be current.
Remicade monitoring test validated for use in IBD patients treated with Inflectra
The Prometheus Anser IFX test has been validated for use in patients with inflammatory bowel disease treated with Inflectra, the manufacturer announced.
Inflectra (Celltrion) is the recently FDA-approved biosimilar of Remicade (infliximab, Janssen), which will be commercialized by Pfizer in the U.S.
“Our data indicate that health care providers can confidently use the Prometheus Anser IFX test, which uniquely measures both serum drug and antidrug antibody levels in the presence of Inflectra (biosimilar infliximab) or Remicade (infliximab) from a single serum sample obtained at any time during treatment,” Tharak Rao, MD, vice president and chief medical officer at Prometheus Laboratories Inc., said in a press release. “The Prometheus Anser IFX test provides critical information that may help a health care provider optimize an IBD patient’s clinical response to biosimilar infliximab or Remicade.”
Specimens from IBD patients treated with Inflectra were used for equivalence testing to validate the test in anticipation of demand from health care providers, according to the press release.
Disclosure: Rao is employed by Prometheus Laboratories.